Pancreatic ductal adenocarcinoma (PDAC), a prominent cause of cancer deaths worldwide,
is a highly aggressive cancer most frequently detected at an advanced stage that limits …

Pancreatic ductal adenocarcinoma (PDAC) has one of the highest mortality rates among all
cancer types. Its delayed diagnosis precludes curative resection, thus most of the current …

Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer-related
deaths in the United States. Although chemotherapeutic regimens such as gemcitabine+ …

Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer-related mortality in
the United States and has only recently achieved a 5-yr survival rate of 10%. This dismal …

Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related
death worldwide, and the mortality of patients with PDAC has not significantly decreased …

Despite the ongoing advances in interventional strategies (surgery, chemotherapy,
radiotherapy, and immunotherapy) for managing pancreatic ductal adenocarcinoma …

Pancreatic cancer (pancreatic ductal adenocarcinoma, PDA) is infamously moving to the top
of the list as one of the most lethal cancers with an overall 5 year survival rate of 7%. Multiple …

Most human cancers display high levels of heterogeneity, a feature that often impacts
negatively on the response to treatments. Indeed, while radio and/or chemotherapy initially …

Pancreatic ductal adenocarcinoma (PDAC), generally known as pancreatic cancer (PC),
ranks the fourth leading cause of cancer-related deaths in the western world. While the …

New research sheds light on the mechanisms underlying resistance to chemotherapeutics in
patients with pancreatic ductal adenocarcinoma (PDAC). Increased expression of CYP3A5 …